On November 1, 2023, Sangamo Therapeutics announced the progression of our strategic transformation to become a neurology-focused genomic medicine company, which has led to other difficult but necessary decisions including deferring any additional investments in the Fabry disease program.

We have shown, and strongly believe in, the promise of ST-920 as a potential medicine for patients suffering with Fabry disease. We are thrilled with the encouraging patient data we have seen to-date with the Phase 1/2 STAAR study. Twenty-five patients have been dosed and all patients continue to demonstrate sustained elevated α-Gal A levels, with 12 patients having achieved at least one year of follow-up and the longest treated patient having now achieved 3 years of follow-up. We have received testimonies from patients saying that the impact of ST-920 has been transformative and who report real and meaningful improvements in their quality of life.

However, in today’s difficult economic environment the costs of progressing this program beyond the current Phase 1/2 study would require significant development and commercial investments, which we do not have the ability to support at this time. We are doing everything in our power to maximize the value of this program, by actively seeking a potential partner or alternative financing to fund a potential Phase 3 trial. We are confident that in the hands of a partner, ST-920 could make an enormous difference to the Fabry community. Since we have reached a sufficient number of patients in the current Phase 1/2 STAAR to provide a preliminary assessment of both safety and efficacy, we have stopped recruitment. We remain committed to those who are in the study.

We will complete the dosing of the remaining patients we have enrolled, and we will continue to follow our existing patients in this trial.

Thank you for your understanding and your shared vision for a healthier future.